posted on 2024-10-22, 21:41authored byRoshan Keshari, Abhay Tharmatt, Mamatha M. Pillai, Deepak Chitkara, Prakriti Tayalia, Rinti Banerjee, Shamik Sen, Rohit Srivastava
Psoriasis is a chronic T-cell-mediated autoimmune skin
disorder
characterized by excessive epidermal thickening, overproliferation
of keratinocyte, disruption of epidermal cell differentiation, and
increased blood vessel growth in the dermal layer. Despite the common
use of corticosteroids in psoriasis treatment, their limited efficacy
and numerous side effects pose significant challenges. This research
introduces a promising alternative approach by encapsulating eugenol
(EU) in soya phosphatidylcholine (SPC) nanoparticles (EUNPs) which
showed spherical shape nanoparticles with a hydrodynamic size of approximately
200 nm, polydispersity index 0.23, encapsulation efficiency of 85%
having good colloidal stability indicated by ζ-potential of
−27 mV. Later on, these EUNPs were formulated into a topical
hydrogel system by using Carbopol 974P (EUNPGel), which exhibited
superior drug loading, enhanced release kinetics for 48 h, long-term
stability, and the ability to scavenge reactive oxygen species (ROS).
Furthermore, EUNPs inhibited keratinocyte proliferation, induced apoptosis,
and augmented the uptake of IL-6-mediated inflammation in human keratinocyte
cells. Application of EUNPs-loaded gels (EUNPGel) to imiquimod-induced
psoriatic lesions demonstrated effective dermal penetration, suppressed
keratinocyte hyperplasia and restored epidermal growth. This led to
a remarkable reduction in the Psoriasis Area and Severity Index (PASI)
score from 3.75 to 0.5 within 5 days. This novel approach enhances
ROS scavenging capacity, improves cellular uptake, facilitates skin
penetration and retention, reduces the activity of hyperactive immune
cells, and suggests potential applications for treating other immune-related
disorders such as acne and atopic dermatitis.